A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-121 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Phase 1
- Conditions
- SCLC
- Registration Number
- JPRN-jRCT2080222600
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Provided written informed consent for treatment.
2. Male or female >=20 years at enrollment.
3. Histologically or cytologically confirmed NSCLC.
4. Have a previous treatment with a single-agent EGFR TKI.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at time of patient's allocation.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method